Gene and Cell Therapy – Products

Atelerix partners with MineBio to bring its pioneering hydrogel-based cell preservation technology to China, enhancing biotech logistics and reducing costs.

Signios Bio, formerly the US research division of MedGenome, has rebranded to reflect its bold vision in AI-powered bioinformatics and multiomics. With an integrated suite of technologies spanning genomics, proteomics and spatial biology.

AMSBIO has broadened its biofluid collection and processing capabilities, now offering a wide range of customizable human blood biospecimens.

Terumo BCT and KBIOHealth have signed an MOU to develop workforce training for cell and gene therapy manufacturing in Korea. The program will focus on CAR-T and MSC therapy production using automated systems like Quantum Flex.

AMSBIO has launched GMP grade StemFit® for Differentiation - a chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.

This application note presents a comprehensive study comparing an ATMP release kit with an alternative PCR-based solution, evaluating both sensitivity and workflow convenience for ATMP quality control laboratories.

Sphere Fluidics announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development.

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a cell-engineering focused company announced the acquisition of SeQure Dx.

Terumo Blood and Cell Technologies (Terumo BCT) and FUJIFILM Irvine Scientific have announced a strategic collaboration to help accelerate T cell expansion.

DNA Script announced a significant advancement in oligonucleotide synthesis technology, enabling the production of custom DNA sequences of up to 500 nucleotides in length with unprecedented sequence complexity.